OTCQX:MRVFF - Post by User
Post by
consultant99on Apr 13, 2017 3:11pm
324 Views
Post# 26119929
April Investor Presentation
April Investor PresentationBottle sales in January and March 2017 were below comparable periods in 2016;
Q1 2017 bottle sales were below Q1 2016.
A $6.5 M increase in revenues in 2016 (vs 2015) lead to a $4.7 M increase in gross margin but only a $0.9 M increase in EBITA.
Results of the Phase III trial are due out in Q2 2017.
Guys we are already 1/6th of the way through Q2 - would it be asking too much or that big a risk to give us a more definitive estimate as to when the results are expected?
The map illustrating out licensing opportunities could be improved if you would identify those countries in which the jurisdictions will base their regulatory approval on US FDA approval.
Potential milestones continue to show that revenues commensing from international licensing will not begin until 2018.
That is a big disappointment that Russian sales are that far off now that they have regulatory approval to market P2%.
Personally my view is the the company continues to miss the mark when it comes to generating enthusiasm to own Nuvo Pharma shares. There is such a lack of clariety around future revenues and timelines that the share price lags behind reasonable price multiples one would expect for a growth company.